Summary

Eligibility
for people ages 45 years and up (full criteria)
Location
at UCLA
Dates
study started
completion around
Principal Investigator
by Dianne S. Cheung, MD, MPH (ucla)
Headshot of Dianne S. Cheung
Dianne S. Cheung

Description

Summary

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

Official Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Keywords

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD), Cardiovascular Disease, Kidney Disease, Major Adverse Cardiovascular Events (MACE), Renal Outcomes, Cardiovascular Risk Reduction, Kidney Disease Progression, Cardiometabolic Risk Factors, Cardiovascular Outcomes, Kidney Outcomes, Type 2 Diabetes, Heart Disease, Coronary Artery Disease, Cerebrovascular Disease, Peripheral Arterial Disease, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Cardiovascular (CV) Death, Hospitalization or Urgent Visit Due to Heart Failure (HF), Renal Death, End Stage Kidney Disease (ESKD), Kidney Diseases, Chronic Renal Insufficiency, Cardiovascular Diseases, Atherosclerosis, Retatrutide

Eligibility

Locations

Lead Scientist at University of California Health

  • Dianne S. Cheung, MD, MPH (ucla)
    HS Associate Clinical Professor, Medicine. Authored (or co-authored) 7 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)
ID
NCT06383390
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 10000 study participants
Last Updated